<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632330</url>
  </required_header>
  <id_info>
    <org_study_id>C0801043</org_study_id>
    <nct_id>NCT03632330</nct_id>
  </id_info>
  <brief_title>Sedation Of Adult Patients Undergoing Gastrointestinal Endoscopy: A Network Meta-analysis</brief_title>
  <official_title>SEDATION OF ADULT PATIENTS UNDERGOING GASTROINTESTINAL ENDOSCOPY: A NETWORK META-ANALYSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety of dexmedetomidine with
      other sedatives in sedation during endoscopy by analyzing the most recently published
      interventional trials and observational studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A variety of sedatives are available in procedural sedation and the efficacy &amp; safety have
      been compared in several trials for procedural sedation. However, none of clinical trial has
      enough number of patients to clarify the conclusive differences among sedatives. Thus,
      pooling all available studies together systematically by network meta-analysis for GI
      endoscopic procedure may provide a better understanding of efficacy and safety of sedatives.
      Therefore we would like to conduct a network meta-analysis to analyze the outcomes of GI
      endoscopy by using the most recently-published interventional trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Actual">March 7, 2018</completion_date>
  <primary_completion_date type="Actual">March 7, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects who experience desaturation</measure>
    <time_frame>From first infusion of the sedative agent until awakening approximately up to 2 hours after the procedure.</time_frame>
    <description>SaO2 &lt; 94% for more than 10 seconds, RR&lt;8, apneic episodes, face mask</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who experience Hypotension</measure>
    <time_frame>From first infusion of the sedative agent until awakening approximately up to 2 hours after the procedure</time_frame>
    <description>BP&lt;90/50, decrease&gt;20% or 10mmHg, MAP&lt;60mmHg or MAP decrease&gt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who experience Bradycardia</measure>
    <time_frame>From first infusion of the sedative agent until awakening approximately up to 2 hours after the procedure</time_frame>
    <description>A heart rate of &lt;50 beats per min, decrease &gt; 15%</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">6963</enrollment>
  <condition>Gastrointestinal Endoscopy</condition>
  <condition>Sedation</condition>
  <condition>Dexmedetomidine</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <description>Dexmedetomidine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <description>Midazolam group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <description>propofol group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam/Propofol</arm_group_label>
    <description>Midazolam and Propofol group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine group</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>The group includes patients treated with Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam group</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>The group includes patients treated with Midazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol group</description>
    <arm_group_label>propofol</arm_group_label>
    <other_name>The group includes patients treated with Propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam/Propofol</intervention_name>
    <description>Midazolam/Propofol group</description>
    <arm_group_label>Midazolam/Propofol</arm_group_label>
    <other_name>The group includes patients treated with Midazolam and propofol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Two reviewers independently extract data, including outcomes of interests, demographics of
        the enrolled patients' population, inclusion and exclusion criteria for each study, the
        comparative drug used, the number of patients in each group, sedation target and posology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Inclusion criteria We will include studies if they (1) the setting was using any
             sedative for endoscopy for an procedural sedation (2) the study compared
             dexmedetomidine with other sedative for sedative therapy and (3) the outcomes included
             satisfaction score and adverse events.

          -  Exclusion criteria We excluded studies if they (1) the number of sedative was
             different in two arms (2) did not report the specific results comparing
             dexmedetomidine with other sedatives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C0801043&amp;StudyName=Sedation+Of+Adult+Patients+Undergoing+Gastrointestinal+Endoscopy%3A+A+Network+Meta-analysis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

